Post_template - Page 8 of 10

BIO Europe Spring Digital Event, March 28–31, 2022

Meet our CBO, Brent Meadows, CEO, Randolf Kerschbaumer, and CSO, Michael Thiele, at the digital BIO-Europe Spring 2022 to learn more about OncoOne’s novel therapies for the treatment of solid tumors and inflammatory/autoimmune diseases.

BIO CEO & Investors Conference, February 14th, 2022, New York, NY, US

Our CEO Randolf Kerschbaumer and our CBO Brent Meadows will attend in person at the hybrid 2022 BIO CEO & Investor Conference in NYC. Randolf will present OncoOne’s corporate highlights and progress live at 10am EST on February 14th, 2022.

OncoOne and GenScript ProBio Enter Agreement for the Manufacturing of Monoclonal Antibody Drugs Targeting oxMIF.

PDF Vienna, Austria – April 8, 2022 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and autoimmune diseases, announced today the presentation of preclinical proof-of-concept data on its lead candidate ON203, a therapeutic monoclonal antibody targeting oxMIF, and the radiodiagnostic 89Zr-ON102,

9th Annual Immuno-Oncology Summit, October 4–6th, 2021, Boston, MA, US

Meet our new CBO, Brent Meadows, at CHI’s 9th Annual Immuno-Oncology Summit in Boston to learn more about OncoOne’s pipeline of novel, anti-cancer therapies for the treatment of solid tumors and inflammation. Please visit OncoOne at poster #6 entitled “Harnessing oxidized macrophage migration inhibitory factor

OncoOne Appoints Brent Meadows as Chief Business Officer

Company establishes U.S. subsidiary as base for strategic partnerships and business development activities- PDF Vienna, Austria – September 15, 2021 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and other indications, announced today the appointment of Brent Meadows to its executive

OncoOne is pleased to welcome Dr. Sara Sajko as our new Scientist.

On September 1, 2021 OncoOne is pleased to welcome Dr. Sara Sajko to our team as a Scientist. Sara will be instrumental in supporting our Biotechnology Group, particularly in antibody design and characterization efforts.

OncoOne is delighted to welcome Dr. Christine Landlinger-Schubert as our new Director of Preclinical Development

On August 2, 2021 OncoOne is delighted to welcome Dr. Christine Landlinger-Schubert as our new Director of Preclinical Development & Project Lead for Inflammation. In her role, Christine will oversee and manage non-clinical studies for our innovative new biotherapeutics.

OncoOne Announces Initiation of IND‐Enabling Studies for Lead Program Targeting Oxidized Macrophage Migration Inhibitory Factor and Secures EUR 1M to Explore Potential in Inflammatory Diseases

Company Secures EUR 1M to Explore Potential in Inflammatory Diseases PDF Vienna, Austria – June 10, 2021 – OncoOne, a biotechnology company focused on discovering precision medicines for cancer and other indications, today announced the start of Investigational New Drug (IND)‐enabling preclinical evaluation for their

OncoOne proudly announces the completion of its first academic thesis.

On May 15, 2021, in Vienna, Austria, OncoOne proudly announces the completion of its first academic thesis. Our team member, Gregor Rossmüller, has successfully conducted and finalized his master’s thesis titled “Purification and characterization of anti-CD3/anti-oxMIF bispecific antibodies or antibody-like molecules for the treatment of

OncoOne introduced Friedmund Bachmann as our new Director of CMC Biologics

On April 1, 2021, OncoOne introduced Friedmund Bachmann as our new Director of CMC Biologics, joining our team in Vienna, Austria. Friedmund will provide valuable support in manufacturing, analytics, and quality control efforts.